Cargando…

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo

BACKGROUND: Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE: The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermersch, Patrick, Radue, Ernst-Wilhelm, Putzki, Norman, Ritter, Shannon, Merschhemke, Martin, Freedman, Mark S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624444/ https://www.ncbi.nlm.nih.gov/pubmed/28989795 http://dx.doi.org/10.1177/2055217317730096

Ejemplares similares

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
por: Kappos, Ludwig, et al.
Publicado: (2015)

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
por: Kappos, Ludwig, et al.
Publicado: (2015)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
por: Bianco, Assunta, et al.
Publicado: (2021)

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials
por: Gärtner, Jutta, et al.
Publicado: (2018)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report
por: Akiyama, Hisanao, et al.
Publicado: (2016)

Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS
por: Deiva, Kumaran, et al.
Publicado: (2020)

Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
por: De Masi, Roberto, et al.
Publicado: (2015)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy after fingolimod treatment
por: Berger, Joseph R., et al.
Publicado: (2018)

Longitudinal Changes in Self-Reported Walking Ability in Multiple Sclerosis
por: Motl, Robert W., et al.
Publicado: (2015)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
por: Arnold, Douglas L, et al.
Publicado: (2020)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2mngfuhhti4tgm3221p11rr2q8